Drug Profile
Sulforafan alfadex - Evgen Pharma
Alternative Names: Broccoli-sprout-extract; SFX-01; Stabilised sulforaphane; STP-2; Sulforadex; Sulforafan-alpha-cyclodextrin; Sulforaphane; Sulforaphane-alpha-cyclodextrin; Sulphoraphane-alfadexLatest Information Update: 18 Jan 2024
Price :
$50
*
At a glance
- Originator Lalilab
- Developer Evgen Pharma
- Class Antihaemorrhagics; Antineoplastics; Behavioural disorder therapies; Chemopreventatives; Phytotherapies
- Mechanism of Action Androgen receptor antagonists; Hedgehog protein modulators; Histone deacetylase inhibitors; NF E2 related factor 2 stimulants; Wnt signalling pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II/III SARS-CoV-2 acute respiratory disease
- Phase II Breast cancer; Subarachnoid haemorrhage
- Phase I Pervasive child development disorders
- Preclinical Glioblastoma; Haematological malignancies; Rhabdomyosarcoma
- No development reported Cardiovascular disorders; Chronic obstructive pulmonary disease; Leukaemia; Multiple sclerosis
Most Recent Events
- 18 Jan 2024 Pharmacodynamics data from a preclinical trial in Rhabdomyosarcoma released by Evgen Pharma (Evgen Pharma pipeline January 2024)
- 16 Jan 2024 Preclinical trials in Rhabdomyosarcoma in United Kingdom (PO) (Evgen Pharma pipeline, January 2024)
- 31 Mar 2023 Evgen Pharma completes phase I trial in volunteers in wales (EudraCT2022-001601-43)